Study Complete
Sponsor ID
20050145
Enbrel Liquid Immunogenicity protocol
Study Details
The purpose of this study is to assess the antibody formation to Enbrel liquid in subjects with Rheumatoid Arthritis
Protocol Summary
Primary Outcome Measures
Rates of anti-etanercept antibody formation to etanercept liquid with or without concomitant methotrexate (MTX) therapy at week 24
Timeframe: 24 weeks
Secondary Outcome Measures
Rates of anti-etanercept antibody formation to etanercept liquid at week 12, and the rates of neutralizing antibodies at Weeks 12 and 24. Safety of etanercept liquid in RA subjects receiving 50 mg once weekly up to 24 weeks.
Timeframe: 12 weeks and 24 weeks
Study Documents
Study Synopsis
Available Language(s): English
Locations
No locations found.